Shares of Ventyx Biosciences Inc.
plunged 73.7% in premarket trading Tuesday, after the biopharmaceutical company said it has decided not to support further development of its plaque psoriasis and psoriatic arthritis treatments. The stock, which was the biggest decliner listed on major U.S. exchanges ahead of the open, was on track to suffer a record one-day selloff and open in record-low territory.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: